Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.S3.305

Prognostic Role of PTEN Gene Expression and Length of Survival of Breast Cancer Patients in the North East of Iran  

Golmohammadi, Rahim (Anatomy Department, Sabzevar University of Medical Sciences)
Rakhshani, Mohammad Hassan (Biostatistics Department, School of Health, Sabzevar University of Medical Sciences)
Moslem, Ali Reza (Anesthesiology Department, Sabzevar University of Medical Sciences)
Pejhan, Akbar (Physiology Department, School of Medicine, Sabzevar University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.sup3, 2016 , pp. 305-309 More about this Journal
Abstract
PTEN protein is an important tumour suppressor factor detectable by immunohistochemistry. The goal of the present study was to investigate the prognostic role of PTEN gene expression focusing on length of survival in breast cancer patients. This descriptive-analytical study was conducted on 100 breast cancer cases referred to Sabzevar hospitals in the north east of Iran between 2010 and 2011, followed up to 2015. The PTEN gene expression of tumour tissue samples was determined using specific monoclonal antibodies. The data were analyzed using Chi-square test and Fisher's exact test. Patient length of survival was analyzed after 4 years of follow-up using the Cox regression model. The PTEN gene was expressed in 70 of 100 samples, while being found at a high level in all noncancerous samples. There was an inverse significant relationship between expression of PTEN and tumour stage and grade (p<0.001). In addition, expression of PTEN in invasive ductal tumours was less than in non-invasive tumours. There was also an inverse significant relationship between the likelihood of death and PTEN gene expression (p<0.01). These findings indicate that lack of PTEN gene expression can be sign for a worse prognosis and poor survival in breast cancer.
Keywords
Breast cancer; PTEN; immunohistochemistry; survival; prognosis;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Baig RM, Mahjabeen I, Sabir M, et al (2011). Genetic changes in the PTEN gene and their association with breast cancer in Pakistan. Asian Pac J Cancer Prev, 12, 2773-8.
2 Bogdanova N, Helbig S, Dork T (2013). Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hered Cancer Clin Pract, 11, 12.   DOI
3 Boosani CS, Agrawal DK (2013). PTEN modulators: a patent review. Expert Opin Ther Pat, 23, 569-80.   DOI
4 Cianfrocca M, Goldstein LJ (2004). Prognostic and predictive factors in early-stage breast cancer. Oncologist, 9, 606-16.   DOI
5 Dean SJ, Perks CM, Holly JM, et al (2014). Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. Am J Clin Pathol, 141, 323-33.   DOI
6 De- Assis LV, Isoldi MC (2013). The function, mechanisms, and role of the genes PTEN and P53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms. Tumour Biol, 35, 889-901.
7 Dunning AM, Healey CS, Pharoah PD, et al (1999). A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 10, 843-54.
8 Golmohammadi R, Pejhan A (2012).The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients. J Pak Med Assoc, 62, 871-5.
9 Golmohammadi R, Namazi MJ, Nikbakht M, et al (2013). Characterization and prognostic value of mutations in exons 5 and 6 of the p53 gene in patients with colorectal Cancers in Central Iran. Gut Liver, 7, 295-302.   DOI
10 Gori S, Sidoni A, Colozza M, et al (2009). EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with rastuzumab. Ann Oncol, 20, 648-54.   DOI
11 Jones N, Bonnet F, Sfar S, et al (2013). Comprehensive analysis of PTEN status in breast carcinomas. Int J Cancer, 133, 323-34.   DOI
12 Kafshdooz L, Kafshdooz T, Tabrizi AD, et al (2015). Role of exon 7 PTEN Gene in Endometrial Carcinoma. Asian Pac J Cancer Prev, 16, 4521-4.   DOI
13 Kitagishi Y, Matsuda S (2013). Redox regulation of tumor suppressor PTEN in cancer and aging (Review). Int J Mol Med, 31, 511-5.   DOI
14 Koo DH, Lee HJ, Ahn JH, et al (2015). Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. Tumour Biol, 36, 5865-71.   DOI
15 Kumar V, Cotran R, Robbins S. et al (2007). Robbins Basic Pathology 8th Edition, Saunders Elsevier, Philadelphia pp 739-50.
16 Lam WW, Fielding R, Ho EY (2005). Predicting psychological morbidity in Chinese women after surgery for breast carcinoma. Cancer, 103, 637-46.   DOI
17 Okutur K, Bassulu N, Dalar L, et al (2015). Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer. Asian Pac J Cancer Prev, 16, 2645-51.   DOI
18 Mandal RK, Akhter N, Irshad M, et al (2015). Association of the PTEN IVS4 (rs3830675) gene polymorphism with reduced risk of cancer: evidence from a meta-analysis. Asian Pac J Cancer Prev, 16, 897-902.   DOI
19 Mayo LD, Dixon JE, Durden DL, et al (2002). PTEN protects p53 from MDM2 and sensitizes cancer cells to chemotherapy. J Biol Chem, 277, 5484-9.   DOI
20 Neto JC, Ikoma MM, Carvalho KC, et al (2012). MGMT and PTEN as potential prognostic markers in breast cancer. Exp Mol Pathol, 92, 20-6.   DOI
21 Sakr RA, Barbashina V, Morrogh M, et al (2010). Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol, 18, 371-4.   DOI
22 Sharif MA, Mamoon N, Arif A, et al (2009). Histological and immuno-histochemical study of male breast carcinoma in Northern Pakistan. J Pak Med Assoc, 59, 67-71.
23 Song MS, Salmena L, Pandolfi PP (2012). The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol, 13, 283-96.   DOI
24 Troyer DA, Jamaspishvili T, Wei W, et al (2015). A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate, 11, 1206-15.
25 Tsutsui S, Inoue H, Yasuda K, et al (2005). Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology, 68, 398-404.   DOI
26 Wikman H, Lamszus K, Detels N, et al (2012). Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res, 14, 49.
27 Van-den Broek AJ, Broeks A, Horlings HM, et al (2011). Association of the germ line TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups. Breast Cancer Res Treat, 130, 599-608.   DOI
28 Wan W, Zou H, Sun R, et al (2007). Cell Signal. Investigate the role of PTEN in chemotaxis of human breast cancer cells. Cell Signal, 19, 2227-36.   DOI
29 Wang S, Gao J, Lei Q, et al (2003). Prostate-specific deletion of the murine PTEN tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 4, 209-21.   DOI
30 Yang J, Ren Y, Wang L, et al (2010). PTEN mutation spectrum in breast cancers and breast hyperplasia. J Cancer Res Clin Oncol, 136, 1303-11.   DOI
31 Yu L, Yang Y, Hou J, et al (2015). Micro RNA-144 affects radiotherapy sensitivity by promoting proliferation, migration and invasion of breast cancer cells. Oncol Rep, 34, 1845-52.   DOI
32 Zhang AX, Lu FQ, Yang YP, et al (2015). Micro RNA-217 over expression induces drug resistance and invasion of breast cancer cells by targeting PTEN signaling. Cell Biol Int, 11, 1299-306.
33 Zhang HY, Liang F, Jia ZL, et al (2013). PTEN mutation, methylation and expression in breast cancer patients. Oncol Lett, 6, 161-8.   DOI
34 Zhou M, Gu L, Findley HW, et al (2003). PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res, 63, 6357-62.